FDA approves first gene therapy for severe LAD-I

Signal

The U.S. Food and Drug Administration approved Kresladi (marnetegragene autotemcel) for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I). The action makes Kresladi the first gene therapy approved for this indication. LAD-I is a rare primary immunodeficiency caused by mutations in the ITGB2 gene, which encodes a protein critical to white blood cell adhesion and immune function. In its severe form, the condition carries a high risk of fatal infection in early childhood without definitive intervention. The approval was announced by the FDA on its official press announcements channel. [VERIFY: confirm exact approval date from the FDA press release at the primary source URL before publication.]

Why it matters

Prior to this approval, allogeneic hematopoietic stem cell transplant (HSCT) was the only potentially curative option for severe LAD-I, and outcomes depended heavily on donor availability and transplant-related risks. An autologous gene therapy approach removes the donor-matching barrier and may reduce the toxicity burden associated with conditioning regimens required for allogeneic transplant. For commercial and access teams, Kresladi enters a rare disease gene therapy market where payers are increasingly scrutinizing one-time, high-cost treatments. Outcomes-based contracting arrangements and coverage-with-evidence-development frameworks have emerged in comparable gene therapy launches - the LAD-I approval is likely to invite similar payer negotiations. Patient population size is very small, which will shape net pricing discussions and budget impact analyses. [VERIFY: confirm any stated patient population estimates or epidemiology figures against the FDA label or the applicant's briefing documents.]

What we are watching

The immediate indicator to track is the Centers for Medicare and Medicaid Services (CMS) coverage determination and any private payer coverage policy filings for Kresladi. Also watch for the manufacturer's announced list price, which will set the baseline for outcomes-based contracting discussions. Longer term, post-marketing safety and efficacy data - particularly on durability of CD18 expression restoration and infection-free survival - will determine whether the clinical profile holds in a broader real-world population beyond the trial cohort. Registry enrollment and any mandated post-approval study timelines from the FDA will be the observable markers to follow.